GlassScriptPhysician profile
Gul K Sahetya
NPI 1922025535
$4,103.83
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $317 · 2021: $1,300 · 2022: $995 · 2023: $603 · 2024: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $918.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,231.37 | 2019-2024 | Xarelto |
| Pfizer INC. | $232.29 | 2021-2024 | |
| Glaxosmithkline, LLC. | $230.55 | 2021-2023 | Arexvy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $229.19 | 2019-2023 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $181.76 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $176.41 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $157.12 | 2019-2023 | Fasenra |
| Inspire Medical Systems, INC. | $153.51 | 2021 | |
| Abbvie INC. | $121.69 | 2021 | |
| Phathom Pharmaceuticals, INC. | $118.00 | 2024 | Voquezna |
| Grifols USA, LLC | $110.89 | 2019-2022 | |
| Allergan, INC. | $99.22 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.25 | 2019-2021 | |
| Philips North America LLC | $88.34 | 2020-2024 | (Ck4) Mcot |
| Harmony Biosciences LLC | $66.81 | 2020-2023 | Wakix |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gul Sahetya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.